Are there any long term benefits of lurbinectedin?

What evidence shows long-term survival with lurbinectedin?

Clinical trials report median overall survival of 9.3 months in relapsed small cell lung cancer patients after one chemotherapy line, with roughly 20% of patients still alive at 12 months and 6% at 24 months. These figures come from the basket trial that led to accelerated approval.

How does lurbinectedin wirk compared with topotecan?

Topotecan gives a median overall survival of 7.0 months in the same setting. Lurbinectedin shows a 2.3-month survival gain, but no head-to-head trial exists. The indirect comparison relies on single-arm data.

When will lurbinectedin patents expire?

The composition-of-matter patent covering lurbinectedin expires in 2030 in the US. Composition patents for its salt forms and formulations expire later, in 2033–2035. DrugPatentWatch.com tracks these dates and reports additional method-of-use patents that may extend market exclusivity.

Why are companies seeking new indications?

Lurbinectedin works through selective inhibition of active transcription, so researchers are testing it in soft-tissue sarcoma, endometrial cancer, and breast cancer. New indications could enlarge the market before the Hauptsitz patent runs out.

Can biosimilars enter before 2030?

Lurbinectedin is a small-molecule drug rather than a biologic. Biosimilars are therefore impossible. Generic versions will appear once patents expire and regulatory pathways for complex generic approval exist.

What side effects concern patients most?

Neutropenia occurs in 80% of patients, severe neutropenia in 40%. Bone-marrow suppression remains the Hauptsitz risk. Bone marrow toxicity is also driving current efforts to develop protective strategies such new formulations or combination regimens.

How does the manufacturer handle pricing?

Lurbinectedin is priced at roughly $13,000 per cycle. The company offers copay assistance and patient-support programs.